<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Healthcare (Basel)</journal-id>
      <journal-id journal-id-type="iso-abbrev">Healthcare (Basel)</journal-id>
      <journal-id journal-id-type="publisher-id">healthcare</journal-id>
      <journal-title-group>
        <journal-title>Healthcare</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2227-9032</issn>
      <publisher>
        <publisher-name>MDPI</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27429133</article-id>
      <article-id pub-id-type="pmc">4934508</article-id>
      <article-id pub-id-type="doi">10.3390/healthcare1010096</article-id>
      <article-id pub-id-type="publisher-id">healthcare-01-00096</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Michael Z.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brewer</surname>
            <given-names>Jerry D.</given-names>
          </name>
          <xref rid="c1-healthcare-01-00096" ref-type="corresp">*</xref>
        </contrib>
      </contrib-group>
      <aff id="af1-healthcare-01-00096">Department of Dermatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; E-Mail: <email>wang08380@gmail.com</email></aff>
      <author-notes>
        <corresp id="c1-healthcare-01-00096"><label>*</label>Author to whom correspondence should be addressed; E-Mail: <email>brewer.jerry@mayo.edu</email>; Tel.: +1-507-284-3579; Fax: +1-507-284-2072.</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>25</day>
        <month>10</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>12</month>
        <year>2013</year>
      </pub-date>
      <volume>1</volume>
      <issue>1</issue>
      <fpage>96</fpage>
      <lpage>99</lpage>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>8</month>
          <year>2013</year>
        </date>
        <date date-type="rev-recd">
          <day>16</day>
          <month>10</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>21</day>
          <month>10</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2013 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement>
        <copyright-year>2013</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/">
          <license-p><!--CREATIVE COMMONS-->This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <p>No particular regimen is considered standard therapy for widespread metastatic melanoma, although surgery is the primary choice for regional nodal metastases. Systemic interleukin-2 (IL-2) is an effective immunotherapy for melanoma, but standard doses are associated with severe toxicity. We report a patient who was treated with intralesional low-dose IL-2 and V-beam pulsed dye laser for the treatment of scalp melanoma metastases. This treatment resulted in rapid regression of metastatic tumors with limited adverse effects.</p>
      </abstract>
      <kwd-group>
        <kwd>interleukin-2</kwd>
        <kwd>melanoma</kwd>
        <kwd>pulsed dye laser therapy</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>1. Introduction</title>
      <p>No particular regimen is considered standard therapy for widespread metastatic melanoma, and effectiveness of single-agent interventions has been questioned [<xref rid="B1-healthcare-01-00096" ref-type="bibr">1</xref>]. Here, we report a new approach with intralesional interleukin-2 (IL-2) and V-beam pulsed dye laser for the treatment of scalp melanoma metastases. </p>
    </sec>
    <sec>
      <title>2. Case Report</title>
      <p>The patient was a 61-year-old man. Twenty-two years ago, a primary melanoma was removed from his neck. Eleven years later, a second primary melanoma developed on his scalp, and was surgically excised. Seven years later, a third melanoma (superficial spreading type) developed on the scalp (Clark level III, Breslow thickness 0.9 mm, and mitotic rate 2/mm<sup>2</sup>), and was treated with wide local excision and sentinel lymph node biopsy. Two lymph nodes harvested were negative. Half a year later, multiple in-transit metastases appeared on his scalp without signs of distant metastases. The lesions were surgically excised. However, multiple in-transit metastases continued to develop in the region rapidly. Thereafter, surgical excision and topical imiquimod 5% were initiated resulting in complete resolution of one lesion, whereas two others persisted.</p>
      <p>The patient was referred to our institution (<xref ref-type="fig" rid="healthcare-01-00096-f001">Figure 1</xref>A). The melanoma was genetically wild-type. Treatment began with systemic granulocyte-macrophage colony-stimulating factor (GMCSF) (250 mcg/day; alternating between 2 weeks of treatments and cessations), topical imiquimod 5% (twice/day), V-beam pulsed dye laser (every 2&#x2013;4 weeks; 595 nm; 10-mm spot size), and periodic punch excisions from June through November 2010. Despite improvement, new lesions continued to develop. Intralesional IL-2 injections (6 million IUs, 2&#x2013;3 times/week) were then added to the therapeutic regimen. Subsequently, within 1 month, all the tumors vanished (<xref ref-type="fig" rid="healthcare-01-00096-f001">Figure 1</xref>A) with pathological confirmation. No severe toxicity was observed, and patient only had flu-like symptoms. Treatment was discontinued in December 2010. The patient remained clinically melanoma-free until July 2011, when a new solitary lesion appeared on vertex scalp. The 0.5 &#xD7; 0.5-cm lesion was a freely mobile, subcutaneous nodule and was confirmed to be metastatic melanoma. IL-2 injections resumed with the previous protocol for a longer period, and complete response was achieved. By September 2011, biopsy showed no residual cancer in the area. </p>
      <fig id="healthcare-01-00096-f001" position="float">
        <label>Figure 1</label>
        <caption>
          <p>(<bold>A1</bold>) In-transit metastasis of melanoma at presentation (referral to our institution); (<bold>A2</bold>) After initial treatment with pulsed dye laser; (<bold>A3</bold>) At the initiation of interleukin-2 injections, in conjunction with continued pulsed dye laser therapy; (<bold>A4</bold>) Four and a half weeks after the addition of interlesional interleukin-2; (<bold>B</bold>) Possible mechanisms of the synergetic effects of intralesional interleukin-2 (IL-2) and local laser therapy.</p>
        </caption>
        <graphic xlink:href="healthcare-01-00096-g001"/>
      </fig>
    </sec>
    <sec>
      <title>3. Results and Discussion</title>
      <p>The management of recurrent melanoma remains challenging. This patient with prolonged but localized in-transit melanoma showed remarkably improved clinical outcome when intralesional IL-2 was added to the interventions. The synergistic effect of IL-2 with V-beam laser is supported by animal models that show enhanced antitumor immunity with judicious combination of immunologic stimulation and laser devitalization of tumor nodules [<xref rid="B2-healthcare-01-00096" ref-type="bibr">2</xref>]. The benefits of systemic IL-2 are offset by its toxicities, limiting its usage to selected patients with advanced metastatic melanoma. We demonstrated that intralesional administration of IL-2 in combination with V-beam laser achieved rapid regression of in-transit metastasis with limited adverse effects. </p>
      <p>IL-2 induced vascular leakage is advantageous in localized treatment because local edema may initiate tumor necrosis that stimulates the immune response. Furthermore, intralesional injection of IL-2 achieves much higher local concentration and limits systemic adverse effects. Therefore a greater therapeutic effect could be expected. Indeed, studies indicated that intralesional IL-2 therapy was more effective than systemic, perilesional, and distant site IL-2 treatments [<xref rid="B3-healthcare-01-00096" ref-type="bibr">3</xref>]. One report showed that a complete local response was achieved in 69% of metastasized melanoma patients (33/48) by intratumorally injection of IL-2 [<xref rid="B4-healthcare-01-00096" ref-type="bibr">4</xref>].</p>
      <p>Preferential absorption of laser radiance by hemoglobin and the subsequent conversion of light energy into thermal energy may cause blood vessel coagulation [<xref rid="B5-healthcare-01-00096" ref-type="bibr">5</xref>], which may enhance the local edematous and ischemic effect of IL-2. In addition, cancer cells are more vulnerable than normal cells to hyperthermia-induced cellular damage [<xref rid="B6-healthcare-01-00096" ref-type="bibr">6</xref>]. Considerable improvement in clinical outcome has been reported after hyperthermic therapy in tumors of many types, including melanoma [<xref rid="B6-healthcare-01-00096" ref-type="bibr">6</xref>]. <xref ref-type="fig" rid="healthcare-01-00096-f001">Figure 1</xref>B summarizes the possible synergetic effect of intralesional IL-2 and V-beam therapy. </p>
    </sec>
    <sec>
      <title>4. Conclusions</title>
      <p>Our results indicate that this combined therapy is a promising strategy for the treatment of in-transit metastatic melanoma. Further study in a larger patient population is warranted.</p>
    </sec>
  </body>
  <back>
    <notes>
      <title>Conflicts of Interest</title>
      <p>The authors declare no conflict of interest.</p>
    </notes>
    <ref-list>
      <title>References</title>
      <ref id="B1-healthcare-01-00096">
        <label>1.</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garbe</surname><given-names>C.</given-names></name><name><surname>Eigentler</surname><given-names>T.K.</given-names></name><name><surname>Keilholz</surname><given-names>U.</given-names></name><name><surname>Hauschild</surname><given-names>A.</given-names></name><name><surname>Kirkwood</surname><given-names>J.M.</given-names></name></person-group>
<article-title>Systematic review of medical treatment in melanoma: Current status and future prospects</article-title>
<source>Oncologist</source>
<year>2011</year>
<volume>16</volume>
<fpage>5</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="pmid">21212434</pub-id></element-citation>
      </ref>
      <ref id="B2-healthcare-01-00096">
        <label>2.</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Katz</surname><given-names>K.A.</given-names></name><name><surname>Jonasch</surname><given-names>E.</given-names></name><name><surname>Hodi</surname><given-names>F.S.</given-names></name><name><surname>Soiffer</surname><given-names>R.</given-names></name><name><surname>Kwitkiwski</surname><given-names>K.</given-names></name><name><surname>Sober</surname><given-names>A.J.</given-names></name><name><surname>Haluska</surname><given-names>F.G.</given-names></name></person-group>
<article-title>Melanoma of unknown primary: Experience at Massachusetts General Hospital and Dana-Farber Cancer Institute</article-title>
<source>Melanoma Res.</source>
<year>2005</year>
<volume>15</volume>
<fpage>77</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1097/00008390-200502000-00013</pub-id>
<pub-id pub-id-type="pmid">15714125</pub-id></element-citation>
      </ref>
      <ref id="B3-healthcare-01-00096">
        <label>3.</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>J.J.</given-names></name><name><surname>Sparendam</surname><given-names>D.</given-names></name><name><surname>den Otter</surname><given-names>W.</given-names></name></person-group>
<article-title>Local interleukin 2 therapy is most effective against cancer when injected intratumourally</article-title>
<source>Cancer Immunol. Immunother.</source>
<year>2005</year>
<volume>54</volume>
<fpage>647</fpage>
<lpage>654</lpage>
<pub-id pub-id-type="doi">10.1007/s00262-004-0627-4</pub-id>
<pub-id pub-id-type="pmid">15685449</pub-id></element-citation>
      </ref>
      <ref id="B4-healthcare-01-00096">
        <label>4.</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weide</surname><given-names>B.</given-names></name><name><surname>Derhovanessian</surname><given-names>E.</given-names></name><name><surname>Pflugfelder</surname><given-names>A.</given-names></name><name><surname>Eigentler</surname><given-names>T.K.</given-names></name><name><surname>Radny</surname><given-names>P.</given-names></name><name><surname>Zelba</surname><given-names>H.</given-names></name><name><surname>Pf&#xF6;hler</surname><given-names>C.</given-names></name><name><surname>Pawelec</surname><given-names>G.</given-names></name><name><surname>Garbe</surname><given-names>C.</given-names></name></person-group>
<article-title>High response rate after intratumoral treatment with interleukin-2: Results from a phase 2 study in 51 patients with metastasized melanoma</article-title>
<source>Cancer</source>
<year>2010</year>
<volume>116</volume>
<fpage>4139</fpage>
<lpage>4146</lpage>
<pub-id pub-id-type="doi">10.1002/cncr.25156</pub-id>
<pub-id pub-id-type="pmid">20564107</pub-id></element-citation>
      </ref>
      <ref id="B5-healthcare-01-00096">
        <label>5.</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Babilas</surname><given-names>P.</given-names></name><name><surname>Shafirstein</surname><given-names>G.</given-names></name><name><surname>Baumler</surname><given-names>W.</given-names></name><name><surname>Baier</surname><given-names>J.</given-names></name><name><surname>Landthaler</surname><given-names>M.</given-names></name><name><surname>Szeimies</surname><given-names>R.M.</given-names></name><name><surname>Abels</surname><given-names>C.</given-names></name></person-group>
<article-title>Selective photothermolysis of blood vessels following flashlamp-pumped pulsed dye laser irradiation: <italic>In vivo</italic> results and mathematical modelling are in agreement</article-title>
<source>J. Invest. Dermatol.</source>
<year>2005</year>
<volume>125</volume>
<fpage>343</fpage>
<lpage>352</lpage>
<pub-id pub-id-type="pmid">16098046</pub-id></element-citation>
      </ref>
      <ref id="B6-healthcare-01-00096">
        <label>6.</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Van der Zee</surname><given-names>J.</given-names></name></person-group>
<article-title>Heating the patient: A promising approach?</article-title>
<source>Ann. Oncol.</source>
<year>2002</year>
<volume>13</volume>
<fpage>1173</fpage>
<lpage>1184</lpage>
<pub-id pub-id-type="doi">10.1093/annonc/mdf280</pub-id>
<pub-id pub-id-type="pmid">12181239</pub-id></element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
